Cargando…

Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes

OBJECTIVE: Diabetic sensorimotor polyneuropathy (DSPN) affects approximately half of diabetic patients leading to significant morbidity. There is impaired neurotrophic growth factor signaling, AMP-activated protein kinase (AMPK) activity and mitochondrial function in dorsal root ganglia (DRG) of ani...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghanoori, Mohamad-Reza, Smith, Darrell R., Shariati-Ievari, Shiva, Ajisebutu, Andrew, Nguyen, Annee, Desmond, Fiona, Jesus, Carlos H.A., Zhou, Xiajun, Calcutt, Nigel A., Aliani, Michel, Fernyhough, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358538/
https://www.ncbi.nlm.nih.gov/pubmed/30545741
http://dx.doi.org/10.1016/j.molmet.2018.11.008
_version_ 1783392009362341888
author Aghanoori, Mohamad-Reza
Smith, Darrell R.
Shariati-Ievari, Shiva
Ajisebutu, Andrew
Nguyen, Annee
Desmond, Fiona
Jesus, Carlos H.A.
Zhou, Xiajun
Calcutt, Nigel A.
Aliani, Michel
Fernyhough, Paul
author_facet Aghanoori, Mohamad-Reza
Smith, Darrell R.
Shariati-Ievari, Shiva
Ajisebutu, Andrew
Nguyen, Annee
Desmond, Fiona
Jesus, Carlos H.A.
Zhou, Xiajun
Calcutt, Nigel A.
Aliani, Michel
Fernyhough, Paul
author_sort Aghanoori, Mohamad-Reza
collection PubMed
description OBJECTIVE: Diabetic sensorimotor polyneuropathy (DSPN) affects approximately half of diabetic patients leading to significant morbidity. There is impaired neurotrophic growth factor signaling, AMP-activated protein kinase (AMPK) activity and mitochondrial function in dorsal root ganglia (DRG) of animal models of type 1 and type 2 diabetes. We hypothesized that sub-optimal insulin-like growth factor 1 (IGF-1) signaling in diabetes drives loss of AMPK activity and mitochondrial function, both contributing to development of DSPN. METHODS: Age-matched control Sprague-Dawley rats and streptozotocin (STZ)-induced type 1 diabetic rats with/without IGF-1 therapy were used for in vivo studies. For in vitro studies, DRG neurons from control and STZ-diabetic rats were cultured and treated with/without IGF-1 in the presence or absence of inhibitors or siRNAs. RESULTS: Dysregulation of mRNAs for IGF-1, AMPKα2, ATP5a1 (subunit of ATPase), and PGC-1β occurred in DRG of diabetic vs. control rats. IGF-1 up-regulated mRNA levels of these genes in cultured DRGs from control or diabetic rats. IGF-1 treatment of DRG cultures significantly (P < 0.05) increased phosphorylation of Akt, P70S6K, AMPK and acetyl-CoA carboxylase (ACC). Mitochondrial gene expression and oxygen consumption rate (spare respiratory capacity), ATP production, mtDNA/nDNA ratio and neurite outgrowth were augmented (P < 0.05). AMPK inhibitor, Compound C, or AMPKα1-specific siRNA suppressed IGF-1 elevation of mitochondrial function, mtDNA and neurite outgrowth. Diabetic rats treated with IGF-1 exhibited reversal of thermal hypoalgesia and, in a separate study, reversed the deficit in corneal nerve profiles. In diabetic rats, IGF-1 elevated the levels of AMPK and P70S6K phosphorylation, raised Complex IV-MTCO1 and Complex V-ATP5a protein expression, and restored the enzyme activities of Complex IV and I in the DRG. IGF-1 prevented TCA metabolite build-up in nerve. CONCLUSIONS: In DRG neuron cultures IGF-1 signals via AMPK to elevate mitochondrial function and drive axonal outgrowth. We propose that this signaling axis mediates IGF-1-dependent protection from distal dying-back of fibers in diabetic neuropathy.
format Online
Article
Text
id pubmed-6358538
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63585382019-02-07 Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes Aghanoori, Mohamad-Reza Smith, Darrell R. Shariati-Ievari, Shiva Ajisebutu, Andrew Nguyen, Annee Desmond, Fiona Jesus, Carlos H.A. Zhou, Xiajun Calcutt, Nigel A. Aliani, Michel Fernyhough, Paul Mol Metab Original Article OBJECTIVE: Diabetic sensorimotor polyneuropathy (DSPN) affects approximately half of diabetic patients leading to significant morbidity. There is impaired neurotrophic growth factor signaling, AMP-activated protein kinase (AMPK) activity and mitochondrial function in dorsal root ganglia (DRG) of animal models of type 1 and type 2 diabetes. We hypothesized that sub-optimal insulin-like growth factor 1 (IGF-1) signaling in diabetes drives loss of AMPK activity and mitochondrial function, both contributing to development of DSPN. METHODS: Age-matched control Sprague-Dawley rats and streptozotocin (STZ)-induced type 1 diabetic rats with/without IGF-1 therapy were used for in vivo studies. For in vitro studies, DRG neurons from control and STZ-diabetic rats were cultured and treated with/without IGF-1 in the presence or absence of inhibitors or siRNAs. RESULTS: Dysregulation of mRNAs for IGF-1, AMPKα2, ATP5a1 (subunit of ATPase), and PGC-1β occurred in DRG of diabetic vs. control rats. IGF-1 up-regulated mRNA levels of these genes in cultured DRGs from control or diabetic rats. IGF-1 treatment of DRG cultures significantly (P < 0.05) increased phosphorylation of Akt, P70S6K, AMPK and acetyl-CoA carboxylase (ACC). Mitochondrial gene expression and oxygen consumption rate (spare respiratory capacity), ATP production, mtDNA/nDNA ratio and neurite outgrowth were augmented (P < 0.05). AMPK inhibitor, Compound C, or AMPKα1-specific siRNA suppressed IGF-1 elevation of mitochondrial function, mtDNA and neurite outgrowth. Diabetic rats treated with IGF-1 exhibited reversal of thermal hypoalgesia and, in a separate study, reversed the deficit in corneal nerve profiles. In diabetic rats, IGF-1 elevated the levels of AMPK and P70S6K phosphorylation, raised Complex IV-MTCO1 and Complex V-ATP5a protein expression, and restored the enzyme activities of Complex IV and I in the DRG. IGF-1 prevented TCA metabolite build-up in nerve. CONCLUSIONS: In DRG neuron cultures IGF-1 signals via AMPK to elevate mitochondrial function and drive axonal outgrowth. We propose that this signaling axis mediates IGF-1-dependent protection from distal dying-back of fibers in diabetic neuropathy. Elsevier 2018-11-28 /pmc/articles/PMC6358538/ /pubmed/30545741 http://dx.doi.org/10.1016/j.molmet.2018.11.008 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Aghanoori, Mohamad-Reza
Smith, Darrell R.
Shariati-Ievari, Shiva
Ajisebutu, Andrew
Nguyen, Annee
Desmond, Fiona
Jesus, Carlos H.A.
Zhou, Xiajun
Calcutt, Nigel A.
Aliani, Michel
Fernyhough, Paul
Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes
title Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes
title_full Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes
title_fullStr Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes
title_full_unstemmed Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes
title_short Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes
title_sort insulin-like growth factor-1 activates ampk to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358538/
https://www.ncbi.nlm.nih.gov/pubmed/30545741
http://dx.doi.org/10.1016/j.molmet.2018.11.008
work_keys_str_mv AT aghanoorimohamadreza insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes
AT smithdarrellr insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes
AT shariatiievarishiva insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes
AT ajisebutuandrew insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes
AT nguyenannee insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes
AT desmondfiona insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes
AT jesuscarlosha insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes
AT zhouxiajun insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes
AT calcuttnigela insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes
AT alianimichel insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes
AT fernyhoughpaul insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes